Autolus Therapeutics plc (AUTL)
$1.62-6.90%Close
SELLCRISIS · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $431M
- Beta
- 2.14
- P/E (TTM)
- -1.53
- Short % float
- 3.49%
- Days to cover
- 5.7
- SI change
- +0.9%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 1
- VALUE
- 6
- GROWTH
- 21
- GARP
- 1
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-107.1%
REV YoY-
ROE-178.6%
EPS YoY-
ROA-56.8%
GROSS16
OP-211
NET-239
[VALUATION]
P/E TTM-1.53
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B5.76
P/FCF-
EV/EBITDA-1.55
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E111.59
ALTMAN Z-
CURR RATIO4.89
ND/EBITDA-
BETA2.14
Company news
FAQ
- What is LOPJLB’s current signal on AUTL?
- LOPJLB’s latest quantitative signal on Autolus Therapeutics plc (AUTL) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is AUTL in?
- Autolus Therapeutics plc (AUTL) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Autolus Therapeutics plc (AUTL) do?
- Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL).…